Dr Md Arifur Rahman

28/05/2026

Wishing you all a very happy Eid Mubarak
I shall resume my OPD at BSH from 6 JUNE 2026 (Saturday)

27/05/2026

Excited to announce that I’ll be presenting at in Sydney from May 31 to June 3! Looking forward to sharing my work and connecting with the community. See you there!

Register now

14/05/2026

06/05/2026

🧠 CNS Cancer Awareness Month | May 2026

Real-world data from BSHL reminds us that CNS malignancies remain one of the most challenging cancers—where delayed diagnosis, limited molecular testing, and difficult tumor locations continue to impact survival outcomes.

📊 In a retrospective analysis from Bangladesh Specialized Hospital (BSHL):
▪ Median overall survival was only 18 months
▪ Patients receiving radiotherapy survived significantly longer (27.5 vs 12.4 months)
▪ Age strongly influenced outcomes
▪ Aggressive histologies such as glioblastoma showed poor survival compared with more indolent tumors
▪ Tumors involving the thalamus or corpus callosum carried particularly poor prognosis

These findings highlight the urgent need for:
✅ Earlier diagnosis
✅ Better access to molecular profiling
✅ Multidisciplinary neuro-oncology care
✅ Improved radiotherapy and supportive care access
✅ Development of Bangladesh-based CNS cancer registries and research

Real-world evidence from our own population is essential to guide future cancer care in Bangladesh.

05/05/2026

Clinical Success Story: Complete Response in Lower Tracheal Malignancy with CCRT

Managing rare airway malignancies often demands a balance of urgency, precision, and multidisciplinary coordination. I would like to share a recent real-world case that highlights the impact of a well-executed multimodal approach.
A 61-year-old female presented with severe airway-compromising symptoms—progressive breathlessness, persistent cough, and hemoptysis. Evaluation confirmed invasive squamous cell carcinoma of the lower trachea (Grade II).
📌 Baseline disease burden:
• Tumor volume: 12.4 cc
• Symptomatic airway compromise
📌 Management strategy:
• Endoscopic debulking with CRYO + APC for immediate airway relief
• Definitive radiotherapy (3DCRT): 54 Gy in 27 fractions
• Concurrent weekly Cisplatin-based chemotherapy (CCRT)
📌 Response dynamics:
• Interim imaging showed 87% tumor reduction (down to 1.6 cc) with nodal clearance
• Final follow-up imaging (May 2026) demonstrated:
✔ Complete radiological response
✔ No residual tracheal mass
✔ No nodal or distant disease
This outcome reinforces several key clinical insights:
🔹 Even in rare central airway tumors, a structured multimodal strategy can achieve curative outcomes
🔹 CCRT remains a powerful organ-preserving approach in patients not suitable for surgery
🔹 Early airway stabilization + timely systemic sensitization is critical
🔹 Real-world data continues to validate outcomes comparable to controlled settings

As we continue to build real-world oncology evidence from Bangladesh, such cases highlight the importance of precision planning, multidisciplinary care, and context-adapted treatment strategies.
Would be interested to hear thoughts from colleagues managing central airway malignancies—especially regarding optimal RT techniques (3DCRT vs IMRT/VMAT) and systemic intensification strategies.